Key Takeaways
- Cardinal Health elevated its fiscal 2026 adjusted EPS outlook to $10.70โ$10.80, compared to the prior range of $10.15โ$10.35.
- Third-quarter adjusted EPS reached $3.17, surpassing the analyst consensus of $2.79.
- Total revenue climbed 11% year-over-year to $60.9 billion, falling short of the $62.1 billion analyst estimate.
- Net income declined to $399 million from $506 million in the prior-year period, impacted by a $184 million goodwill impairment.
- CAH shares gained 1.6% during premarket trading on Thursday.
Cardinal Health delivered its second upward revision to full-year earnings expectations this year, prompting investor enthusiasm. Shares advanced 1.6% in Thursday’s premarket session to reach $205.99.
The healthcare distributor now projects adjusted earnings between $10.70 and $10.80 per share for fiscal year 2026. This represents a notable increase from the February forecast range of $10.15 to $10.35. Wall Street analysts had been modeling approximately $10.31 per share.
The upgraded outlook overshadowed what was otherwise an inconsistent quarterly performance.
On the earnings front, adjusted EPS of $3.17 significantly exceeded the $2.79 consensus estimate. Such a substantial beat typically captures market attention.
Revenue results painted a more complicated picture. While total sales increased 11% year-over-year to $60.9 billion, the figure came in below the $62.1 billion that analysts had anticipated.
The pharmaceutical and specialty solutions division accounted for the bulk of revenue expansion, generating $56.1 billionโan 11% increase compared to the same quarter last year.
Meanwhile, the global medical products and distribution segment struggled. Sales in this division remained essentially unchanged from the prior year, hampered by reduced distribution volumes.
Bottom Line Under Pressure
Net income fell to $399 million from $506 million recorded in the year-ago quarter. The primary driver was a $184 million pretax goodwill impairment charge.
This impairment related to Cardinal’s oncology practice alliance and its Integrated Oncology Network, an asset the company acquired in late 2024.
While goodwill impairments don’t represent actual cash outflows, they indicate that an acquired business is underperforming relative to initial purchase expectations. Such charges warrant investor attention.
Evercore ISI analyst Elizabeth Anderson characterized the results as “solid,” explaining that the pharmaceutical revenue shortfall stemmed mainly from wholesale acquisition cost dynamicsโa passthrough matter rather than a core operational concern.
Specialty Pharmaceutical Growth Drives Confidence
Cardinal Health, alongside competitors Cencora and McKesson, continues benefiting from robust demand for high-margin specialty pharmaceuticals. Medications for cancer treatment and autoimmune disorders represent an expanding portion of the distribution portfolio.
Biosimilar launches for major off-patent drugs are also contributing to volume growth. These products enable distributors to capture superior margins compared to conventional generic medications.
Cardinal has been strategically broadening its specialty care presence through acquisitions of physician practices and specialized distribution networks. The Integrated Oncology Network transaction exemplified this strategic direction.
This approach hasn’t been entirely smoothโas evidenced by this quarter’s impairment charge. Nevertheless, management appears committed to this strategic trajectory.
The second consecutive full-year guidance increase indicates management’s confidence regarding performance in the remaining fiscal months.
Cardinal Health’s fiscal third quarter concluded on March 31. At the time of reporting, the stock traded 1.6% higher in premarket activity at $205.99.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
